Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxxinity

Full company profile

uuid0000eeq

Namestring
Vaxxinity
Legal namestring
Vaxxinity, Inc.
Websiteurl
vaxxinity.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Vaxxinity is a clinical-stage biotechnology company developing a pipeline of synthetic peptide vaccines based on its proprietary Active Immunotherapy Medicine (AIM) platform. The platform uses synthetic peptides designed to mimic biological epitopes, selectively activating the immune system to overcome immune tolerance and stimulating the body to produce its own therapeutic antibodies. The company targets three primary disease areas: neurodegenerative diseases (Alzheimer's via UB-311 and Parkinson's via UB-312), infectious disease (COVID-19 booster UB-612, which completed Phase 3), and cardiovascular disease (anti-PCSK9 cholesterol vaccine VXX-401, in preclinical development). AIM-based products are differentiated by conventional 2-8°C cold chain storage requirements, eliminating the need for frozen infrastructure needed by mRNA vaccines, and by synthetic, scalable, low-cost manufacturing.

The company's pipeline has accumulated 10 completed human clinical trials, multiple peer-reviewed publications in Nature Medicine, The Lancet, and Movement Disorders journals, and a Phase 3 success for UB-612. It has established research partnerships with CEPI, the University of Florida's Center for Translational Research in Neurodegenerative Disease, and the University of Central Florida, plus a Frontier Exploration Laboratory in Florida. Revenue is effectively zero: no products are commercialized, pricing is not publicly disclosed, and the company is funded through grants and prior capital rather than product sales. In April 2024, Vaxxinity announced its intention to voluntarily delist from Nasdaq and deregister its Class A common stock, suspending public reporting obligations.

Short descriptiontext

Vaxxinity is a clinical-stage biotechnology company developing synthetic peptide vaccines using its proprietary AIM platform to treat and prevent infectious, neurodegenerative, and cardiovascular diseases, with all pipeline assets in clinical or preclinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCape Canaveral, United States
HQ citystring
Cape Canaveral
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic peptide vaccines, active immunotherapy, neurodegenerative disease therapeutics, preventive vaccines, biopharmaceutical research
Industry4 codes
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Vaccines / Biopharmaceuticals
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaxxinity develops a pipeline of synthetic peptide-based active immunotherapy vaccine candidates built on its proprietary AIM (Active Immunotherapy Medicine) platform. The pipeline targets chronic and infectious diseases — including Alzheimer's (UB-311), Parkinson's (UB-312), COVID-19 (UB-612), and elevated LDL cholesterol (VXX-401) — by stimulating the patient's own immune system to produce therapeutic antibodies. Products are designed to be low-cost, scalable, and storable at conventional 2–8°C cold chain temperatures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • UB-312 is first Parkinson's candidate to reduce pathology as measured by seed amplification assay
+2 more records
Product overview1 text field

Vaxxinity is developing a pipeline of active immunotherapies based on its proprietary AIM (Active Immunotherapy Medicine) platform. The platform uses synthetic peptides to convert the body into its own antibody factory. The product portfolio includes UB-612 (COVID-19 booster vaccine), UB-311 (Alzheimer's disease vaccine), UB-312 (Parkinson's disease vaccine), and VXX-401 (cholesterol-lowering vaccine), all designed to stimulate the immune system to produce therapeutic antibodies against specific disease targets.

Product and service4 records
1UB-612 (COVID-19 Booster Vaccine)
CategoryTherapeutic / preventive vaccine — infectious disease
Description

Multitope protein-peptide COVID-19 booster vaccine designed to be effective against emerging SARS-CoV-2 variants, with no frozen cold chain, no mRNA, and no spike protein. The candidate completed a Phase 3 trial meeting all endpoints, targeting the general population needing COVID-19 booster vaccination.

2UB-311 (Alzheimer's Disease Vaccine)
CategoryTherapeutic vaccine — neurodegenerative disease
Description

Active immunotherapy vaccine candidate targeting amyloid beta peptides for patients with mild Alzheimer's disease, designed to overcome immune tolerance and stimulate the patient's own antibody production. Phase 2a clinical trial completed with demonstrated safety, tolerability, immunogenicity, and efficacy.

3UB-312 (Parkinson's Disease Vaccine)
CategoryTherapeutic vaccine — neurodegenerative disease
Description

Active immunotherapy vaccine candidate targeting pathological alpha-synuclein for patients with Parkinson's disease. Phase 1 trial demonstrated target engagement and immunogenicity, and the program produced the first Parkinson's candidate to reduce pathology as measured by seed amplification assay.

4VXX-401 (Anti-PCSK9 Cholesterol Vaccine)
CategoryTherapeutic vaccine — cardiovascular disease prevention
Description

Anti-PCSK9 vaccine candidate designed to lower LDL cholesterol (LDL-C) for patients requiring cholesterol management via a preventive vaccination approach. Preclinical data published in the Journal of Lipid Research shows robust LDL-C reduction in cynomolgus monkeys with no safety signals observed.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1University of Florida (UF) Center for Translational Research in Neurodegenerative Disease (CTRND)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Research collaboration to support development of active immunotherapies for neurodegenerative diseases. Funded by a grant from the state of Florida. Aims to develop vaccines that could change the future of treatment by offering affordable and accessible therapeutic options.

vaxxinity.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-18
Description

Collaboration to advance space medicine research funded by a grant from the State of Florida. Focuses on developing active immunotherapies to prevent and mitigate muscle and bone wasting related to long-term spaceflight, which share biological mechanisms with age-related diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recombinant protein subunit vaccine developer with COVID-19 and broader infectious disease pipeline. Direct peer in protein-based vaccine modality competing for similar booster and primary vaccine market, though with larger platform footprint.

TypeDirect peer
Description

Clinical-stage biotech developing active immunotherapies and diagnostics targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Closest direct peer given overlapping indication focus on active immunization approaches to neuro targets.

TypeBroad incumbent
Description

mRNA vaccine leader with approved COVID-19 vaccine and broad pipeline including infectious disease, oncology, and rare disease programs. Broad incumbent competing in the same indications (COVID-19, flu) but with much larger commercial reach and capital base.

TypeBroad incumbent
Description

mRNA vaccine leader co-developing Comirnaty with Pfizer; also pursuing oncology and infectious disease programs. Competes with Vaxxinity in COVID-19 booster market and increasingly in infectious-disease mRNA applications.

TypeDirect peer
Description

Clinical-stage vaccine company developing virus-like particle (VLP) and enveloped VLP vaccines for infectious disease and immuno-oncology. Similar size, similar clinical-stage profile, and overlapping infectious-disease focus make it a strong comparability match.

TypeDirect peer
Description

mRNA-based vaccine developer with a focus on infectious disease including COVID-19, rabies, and other indications. Competes in the same vaccine modality space, with comparable clinical-stage pipeline profile for infectious-disease applications.

TypeEmerging player
Description

Commercial-stage vaccine company with HEPLISAV-B hepatitis B vaccine and CpG 1018 adjuvant used across multiple partner vaccine programs. Relevant peer given shared vaccine adjuvants/formulation focus and infectious-disease end markets.

TypeEmerging player
Description

Clinical-stage company developing oral pill vaccines, including for COVID-19 and norovirus. Comparable in size and stage, with a different delivery modality but similar mission of differentiated vaccine formats targeting infectious disease.

TypeEmerging player
Description

Clinical-stage immuno-oncology and vaccine company developing B-cell immunotherapies and oncolytic virotherapies. Comparable as a small-cap peptide/immunotherapy platform company targeting novel vaccine-like modalities, though with an oncology focus.

TypeEmerging player
Description

Pre-commercial immunology company developing therapies for immune-mediated diseases, including a T1D delay therapy. Comparable in size and stage as a small clinical-stage immunology company that exited via acquisition, providing a relevant M&A-comparable precedent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxxinity

Therapeutic Vaccines / Biopharmaceuticalsvaxxinity.com

Vaxxinity is a clinical-stage biotechnology company developing synthetic peptide vaccines using its proprietary AIM platform to treat and prevent infectious, neurodegenerative, and cardiovascular diseases, with all pipeline assets in clinical or preclinical development.

What Vaxxinity does

Vaxxinity is a clinical-stage biotechnology company developing a pipeline of synthetic peptide vaccines based on its proprietary Active Immunotherapy Medicine (AIM) platform. The platform uses synthetic peptides designed to mimic biological epitopes, selectively activating the immune system to overcome immune tolerance and stimulating the body to produce its own therapeutic antibodies. The company targets three primary disease areas: neurodegenerative diseases (Alzheimer's via UB-311 and Parkinson's via UB-312), infectious disease (COVID-19 booster UB-612, which completed Phase 3), and cardiovascular disease (anti-PCSK9 cholesterol vaccine VXX-401, in preclinical development). AIM-based products are differentiated by conventional 2-8°C cold chain storage requirements, eliminating the need for frozen infrastructure needed by mRNA vaccines, and by synthetic, scalable, low-cost manufacturing.

The company's pipeline has accumulated 10 completed human clinical trials, multiple peer-reviewed publications in Nature Medicine, The Lancet, and Movement Disorders journals, and a Phase 3 success for UB-612. It has established research partnerships with CEPI, the University of Florida's Center for Translational Research in Neurodegenerative Disease, and the University of Central Florida, plus a Frontier Exploration Laboratory in Florida. Revenue is effectively zero: no products are commercialized, pricing is not publicly disclosed, and the company is funded through grants and prior capital rather than product sales. In April 2024, Vaxxinity announced its intention to voluntarily delist from Nasdaq and deregister its Class A common stock, suspending public reporting obligations.

Vaxxinity firmographics

Firmographics
Name
Vaxxinity
Legal name
Vaxxinity, Inc.
Website
https://vaxxinity.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Vaxxinity is a clinical-stage biotechnology company developing synthetic peptide vaccines using its proprietary AIM platform to treat and prevent infectious, neurodegenerative, and cardiovascular diseases, with all pipeline assets in clinical or preclinical development.
Ownership category
akta.pro rank

Vaxxinity industry classification

Industry
Product category
Therapeutic Vaccines / Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Synthetic peptide vaccines
  • Active immunotherapy
  • Neurodegenerative disease therapeutics
  • Preventive vaccines
  • Biopharmaceutical research

Where Vaxxinity is headquartered

Location

Headquarters

HQ city
Cape Canaveral
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vaxxinity business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Vaxxinity product offering

Product offering

Core offering

Vaxxinity develops a pipeline of synthetic peptide-based active immunotherapy vaccine candidates built on its proprietary AIM (Active Immunotherapy Medicine) platform. The pipeline targets chronic and infectious diseases — including Alzheimer's (UB-311), Parkinson's (UB-312), COVID-19 (UB-612), and elevated LDL cholesterol (VXX-401) — by stimulating the patient's own immune system to produce therapeutic antibodies. Products are designed to be low-cost, scalable, and storable at conventional 2–8°C cold chain temperatures.

Product overview

Vaxxinity is developing a pipeline of active immunotherapies based on its proprietary AIM (Active Immunotherapy Medicine) platform. The platform uses synthetic peptides to convert the body into its own antibody factory. The product portfolio includes UB-612 (COVID-19 booster vaccine), UB-311 (Alzheimer's disease vaccine), UB-312 (Parkinson's disease vaccine), and VXX-401 (cholesterol-lowering vaccine), all designed to stimulate the immune system to produce therapeutic antibodies against specific disease targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • UB-612 (COVID-19 Booster Vaccine) Multitope protein-peptide COVID-19 booster vaccine designed to be effective against emerging SARS-CoV-2 variants, with no frozen cold chain, no mRNA, and no spike protein. The candidate completed a Phase 3 trial meeting all endpoints, targeting the general population needing COVID-19 booster vaccination.
  • UB-311 (Alzheimer's Disease Vaccine) Active immunotherapy vaccine candidate targeting amyloid beta peptides for patients with mild Alzheimer's disease, designed to overcome immune tolerance and stimulate the patient's own antibody production. Phase 2a clinical trial completed with demonstrated safety, tolerability, immunogenicity, and efficacy.
  • UB-312 (Parkinson's Disease Vaccine) Active immunotherapy vaccine candidate targeting pathological alpha-synuclein for patients with Parkinson's disease. Phase 1 trial demonstrated target engagement and immunogenicity, and the program produced the first Parkinson's candidate to reduce pathology as measured by seed amplification assay.
  • VXX-401 (Anti-PCSK9 Cholesterol Vaccine) Anti-PCSK9 vaccine candidate designed to lower LDL cholesterol (LDL-C) for patients requiring cholesterol management via a preventive vaccination approach. Preclinical data published in the Journal of Lipid Research shows robust LDL-C reduction in cynomolgus monkeys with no safety signals observed.

Quantifiable outcome

  • UB-312 is first Parkinson's candidate to reduce pathology as measured by seed amplification assay
  • +2 more outcomes

Companies that use Vaxxinity

Customer profile

Segments3 records

Ideal customer profiles2 records

Vaxxinity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vaxxinity partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University of Florida (UF) Center for Translational Research in Neurodegenerative Disease (CTRND)coreStrategic or Co-development Partner · 30 January 2024Research collaboration to support development of active immunotherapies for neurodegenerative diseases. Funded by a grant from the state of Florida. Aims to develop vaccines that could change the future of treatment by offering affordable and accessible therapeutic options.
  • University of Central Florida (UCF)coreStrategic or Co-development Partner · 18 January 2024Collaboration to advance space medicine research funded by a grant from the State of Florida. Focuses on developing active immunotherapies to prevent and mitigate muscle and bone wasting related to long-term spaceflight, which share biological mechanisms with age-related diseases.

Scale indicators3 records

Recent moves7 records

Expansion highlights3 records

Vaxxinity competitors and assessment

Company assessment

Direct peers

  • Novavax: Recombinant protein subunit vaccine developer with COVID-19 and broader infectious disease pipeline. Direct peer in protein-based vaccine modality competing for similar booster and primary vaccine market, though with larger platform footprint.
  • AC Immune: Clinical-stage biotech developing active immunotherapies and diagnostics targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Closest direct peer given overlapping indication focus on active immunization approaches to neuro targets.
  • VBI Vaccines: Clinical-stage vaccine company developing virus-like particle (VLP) and enveloped VLP vaccines for infectious disease and immuno-oncology. Similar size, similar clinical-stage profile, and overlapping infectious-disease focus make it a strong comparability match.
  • CureVac: mRNA-based vaccine developer with a focus on infectious disease including COVID-19, rabies, and other indications. Competes in the same vaccine modality space, with comparable clinical-stage pipeline profile for infectious-disease applications.

Broad incumbents

  • Moderna: mRNA vaccine leader with approved COVID-19 vaccine and broad pipeline including infectious disease, oncology, and rare disease programs. Broad incumbent competing in the same indications (COVID-19, flu) but with much larger commercial reach and capital base.
  • BioNTech: mRNA vaccine leader co-developing Comirnaty with Pfizer; also pursuing oncology and infectious disease programs. Competes with Vaxxinity in COVID-19 booster market and increasingly in infectious-disease mRNA applications.

Emerging players

  • Dynavax Technologies: Commercial-stage vaccine company with HEPLISAV-B hepatitis B vaccine and CpG 1018 adjuvant used across multiple partner vaccine programs. Relevant peer given shared vaccine adjuvants/formulation focus and infectious-disease end markets.
  • Vaxart: Clinical-stage company developing oral pill vaccines, including for COVID-19 and norovirus. Comparable in size and stage, with a different delivery modality but similar mission of differentiated vaccine formats targeting infectious disease.
  • Imugene: Clinical-stage immuno-oncology and vaccine company developing B-cell immunotherapies and oncolytic virotherapies. Comparable as a small-cap peptide/immunotherapy platform company targeting novel vaccine-like modalities, though with an oncology focus.
  • Provention Bio: Pre-commercial immunology company developing therapies for immune-mediated diseases, including a T1D delay therapy. Comparable in size and stage as a small clinical-stage immunology company that exited via acquisition, providing a relevant M&A-comparable precedent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vaxxinity social profiles

Digital presence

Vaxxinity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxxinity leadership team

Management profile

Number of profiles

Profiles11 records

Vaxxinity funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxxinity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxxinity

What does Vaxxinity do?

Vaxxinity develops a pipeline of synthetic peptide-based active immunotherapy vaccine candidates built on its proprietary AIM (Active Immunotherapy Medicine) platform. The pipeline targets chronic and infectious diseases — including Alzheimer's (UB-311), Parkinson's (UB-312), COVID-19 (UB-612), and elevated LDL cholesterol (VXX-401) — by stimulating the patient's own immune system to produce therapeutic antibodies. Products are designed to be low-cost, scalable, and storable at conventional 2–8°C cold chain temperatures.

Is Vaxxinity a public or private company?

Vaxxinity is a public company. It is classified as public and is currently operating.

When was Vaxxinity founded?

Vaxxinity was founded in 2019. It employs 11 to 50 people.

Where is Vaxxinity based?

Vaxxinity is headquartered in Cape Canaveral, United States, in the North America region.

Who are Vaxxinity's main competitors?

Direct peers on record are Novavax, AC Immune, VBI Vaccines and CureVac. Broad incumbents are Moderna and BioNTech. Emerging players are Dynavax Technologies, Vaxart, Imugene and Provention Bio.

Does Vaxxinity have an API?

No public API is recorded for Vaxxinity.

What industry is Vaxxinity in?

Vaxxinity's product category is Therapeutic Vaccines / Biopharmaceuticals. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaWhy Vaxxinity (VAXX) Shares Are Volatile Today - VAXXINITY INC A by Vaxxinity, Inc. (OTC:VAXX)Vaxxinity Inc announced its intention to voluntarily delist and deregister its Class A common stock from Nasdaq due to non-compliance with the minimum bid price requirement. The company's shares are trading lower by 10% to $0.24 during Tuesday's session, with a 52-week high of $3.10 and a 52-week low of $0.19. The delisting is set to occur around May 9, after which the company may trade on over-the-counter markets while focusing its resources on research and development.BenzingaWhy Vaxxinity (VAXX) Shares Are Down Nearly 50% - VAXXINITY INC A by Vaxxinity, Inc. (OTC:VAXX)Vaxxinity Inc (NASDAQ:VAXX) announced plans to voluntarily delist and deregister its Class A common stock from Nasdaq, causing shares to drop 47% to $0.25 during Monday's trading session. The company cited non-compliance with Nasdaq's minimum bid price requirement and stated that low trading value and volume have hindered its ability to raise capital and attract investor interest. The delisting is expected to take effect around May 9, after which the company may trade on over-the-counter markets while focusing resources on research and development without stock price distractions.YahooPeek inside the Space Coast vaccine lab working to create humanity’s moonshotVaxxinity scientists in Brevard County are developing peptide-based vaccines for Alzheimer's, Parkinson's, and other degenerative diseases. The process takes a year to identify a candidate peptide and 18 months of animal testing before human trials. The company aims to hand off research to larger firms for regulatory approval.BenzingaVaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial - VAXXINITY INC A by VaxxinitVaxxinity Inc announced results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease. The trial met its primary objectives with 92% of patients (12 out of 13) who completed dosing developing anti-aSyn antibodies, and the vaccine was well-tolerated. The Michael J. Fox Foundation is funding further collaborative research to characterize the antibodies and evaluate UB-312's potential.GlobeNewswireVaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612Vaxxinity announced positive topline data from its Phase 3 trial of UB-612, a COVID-19 booster, showing superior neutralizing antibody titers and seroconversion rates against Wuhan and Omicron BA.5 variants compared to three authorized vaccines. The company expects to submit marketing applications to the MHRA and TGA in H1 2023 for conditional approval in the UK and Australia.BenzingaWhy Vaxxinity (VAXX) Shares Are Trading Higher Today - VAXXINITY INC A by Vaxxinity, Inc. (OTC:VAXX)Vaxxinity Inc announced preclinical data showing its VXX-401 anti-PCSK9 vaccine candidate produced durable LDL cholesterol reductions of 40-50% versus placebo in non-human primates, with plans to initiate Phase 1 clinical trials in early 2023. The synthetic peptide vaccine demonstrated long-lasting steady-state LDL reduction comparable to monoclonal antibody treatment, without affecting HDL cholesterol levels. Shares of VAXX rose 8.28% to $2.08 following the announcement.BenzingaInsiders Buy More Than $21M Of 3 Penny Stocks - Rekor Systems (NASDAQ:REKR), VAXXINITY INC A by VaxxinityInsiders purchased shares worth over $21 million across three penny stocks, with the largest transaction being Wave Life Sciences director Rajeev Shah acquiring 9.48 million shares for approximately $20.38 million following a share offering. The other notable insider purchases were Arctis Global LLC acquiring 243,902 Rekor Systems shares for $523,800 and United Biomedical Inc acquiring 100,000 Vaxxinity shares for $199,290. Rekor Systems also received a contract from Missouri DOT for AI-driven traffic solutions, while Vaxxinity reported a narrower-than-expected quarterly loss last month.BenzingaHow Is The Market Feeling About Vaxxinity? - VAXXINITY INC A by Vaxxinity, Inc. (OTC:VAXX)Vaxxinity's short interest rose 32.76% since its last report, with 278.70 thousand shares sold short, representing 0.77% of float. The company's short interest is below its peer group average of 10.17%.BenzingaVaxxinity Gets Fast Track designation from FDA For Alzheimer's disease Candidate UB-311 - VAXXINITY INC AVaxxinity, Inc. announced that its Alzheimer's disease candidate UB-311 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The company plans to initiate a Phase 2b trial for the drug in late 2022, following positive safety data from Phase 2a clinical trials.BenzingaVaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial - VAXXINITY INC A bCEPI (Coalition for Epidemic Preparedness Innovations) will co-fund Vaxxinity Inc's ongoing global Phase 3 trial of the next-generation UB-612 COVID-19 vaccine candidate with up to $9.25 million in funding. The trial, which began in the US earlier this year, is evaluating UB-612 as a heterologous booster dose in approximately 1,000 healthy adults aged 16 years or older previously immunized with authorized COVID-19 vaccines. Primary immunogenicity analyses are expected in the second half of 2022, and if successful, the study may support conditional approval of UB-612 as discussed with global regulators.